STOCK TITAN

Revance Therapeutics Inc - RVNC STOCK NEWS

Welcome to our dedicated news page for Revance Therapeutics (Ticker: RVNC), a resource for investors and traders seeking the latest updates and insights on Revance Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Revance Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Revance Therapeutics's position in the market.

Rhea-AI Summary
RVNC: Revance Therapeutics Reports Q3 Total Revenue of $56.8M, DAXXIFY Approval for Cervical Dystonia, and Positive Sales Growth. Q3 DAXXIFY revenue of $22.0M, RHA Collection revenue of $32.1M, and total product revenue of $54.1M, a YoY increase of 107.5%. DAXXIFY approval by FDA for cervical dystonia marks a significant milestone in the therapeutics market. Conference call and webcast today at 4:30 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.05%
Tags
-
Rhea-AI Summary
RVNC: Revance Therapeutics Appoints Erica Jordan as Chief Commercial Officer, Aesthetics. The company aims to drive DAXXIFY adoption and grow its RHA filler business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.05%
Tags
management
-
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) will be participating in two investor conferences: Stifel 2023 Healthcare Conference and Piper Sandler 35th Annual Healthcare Conference. The Chief Financial Officer, Tobin Schilke, will participate in a fireside chat on November 14, 2023, at 11:30 A.M. EST, while the Chief Executive Officer, Mark Foley, will participate in a fireside chat on November 28, 2023, at 3:00 P.M. EST. Interested parties can access the live audio webcasts from the company's website. Webcast replays will be available for approximately 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
conferences
Rhea-AI Summary
Revance Therapeutics, Inc. (RVNC) will release its third quarter 2023 financial results on November 8, 2023, after the market closes. A conference call and live webcast will be held on the same day at 4:30 p.m. ET to discuss the results and provide a corporate update. Interested individuals can dial (833) 470-1428 to listen to the conference call or access the webcast link on the company's website. A webcast replay will be available until February 8, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
-
Rhea-AI Summary
DAXXIFY® for Injection named to TIME’s list of the best inventions of 2023. DAXXIFY® is a long-lasting peptide enhanced neuromodulator that delivers the first true innovation in neuromodulator formulation in more than 30 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
none
-
Rhea-AI Summary
Revance Therapeutics hosts Investor Day, announces new pricing program for DAXXIFY®, expects long-term supply chain strategy to support over 80% adjusted gross margin. Expects to free up $20 million/year by exiting OPUL® payments business. Updates 2023 financial guidance, funded to breakeven and expects to be Adjusted EBITDA positive in 2025. Q3 2023 product revenue potential similar to Q2 2023 levels. Revised operating expense guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.31%
Tags
none
Rhea-AI Summary
Revance Therapeutics to host Investor Day on September 19, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
conferences
-
Rhea-AI Summary
Revance Therapeutics receives FDA approval for DAXXIFY® for the treatment of cervical dystonia, expanding its market opportunity in the $2.5 billion U.S. therapeutic neuromodulator market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.05%
Tags
Rhea-AI Summary
RVNC: Revance Therapeutics to Release Q2 2023 Financial Results on August 8, 2023; Conference Call Scheduled for Same Day at 4:30 p.m. ET. Webcast Replay Available Until November 9, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
Revance Therapeutics Inc

Nasdaq:RVNC

RVNC Rankings

RVNC Stock Data

430.41M
70.80M
8.48%
76.13%
13%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Newark

About RVNC

revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form